1. Home
  2. INLX vs TPST Comparison

INLX vs TPST Comparison

Compare INLX & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellinetics Inc.

INLX

Intellinetics Inc.

HOLD

Current Price

$6.70

Market Cap

30.4M

Sector

Technology

ML Signal

HOLD

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$1.77

Market Cap

30.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLX
TPST
Founded
1996
2011
Country
United States
United States
Employees
98
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.4M
30.9M
IPO Year
2013
2012

Fundamental Metrics

Financial Performance
Metric
INLX
TPST
Price
$6.70
$1.77
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$11.00
AVG Volume (30 Days)
1.7K
140.9K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,336.00
$295,000.00
Revenue This Year
$16.86
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.45
$1.50
52 Week High
$14.57
$12.22

Technical Indicators

Market Signals
Indicator
INLX
TPST
Relative Strength Index (RSI) 41.75 44.02
Support Level N/A $1.57
Resistance Level $8.12 $2.48
Average True Range (ATR) 0.29 0.15
MACD -0.02 -0.01
Stochastic Oscillator 18.66 11.09

Price Performance

Historical Comparison
INLX
TPST

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Software and Document Services. The Software segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Services offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Services Segment.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Share on Social Networks: